QNRX फॉरेक्स के समाचार

Quoin Pharmaceuticals Ltd. (QNRX) announced Monday that the U.S. Food and Drug Administration (FDA) has cleared the recruitment of teen subjects aged 14 years and older into its two ongoing clinical trials for QRX003, which is being developed as a potential treatment for Netherton Syndrome (NS).